Stock Track | Arcus Biosciences Soars 13.38% as Analysts Upgrade Stock and Raise Price Targets

Stock Track
02-26

Arcus Biosciences Inc. (RCUS) stock soared 13.38% on Wednesday in pre-market trading hours. The biopharmaceutical company's shares were boosted by multiple analyst upgrades and increased price targets.

Barclays analyst Peter Lawson maintained a Buy rating on Arcus and set a price target of $29.00. HC Wainwright also upgraded Arcus to Buy from Neutral and raised their price target to $24 from $18, citing the company's strong pipeline and growth prospects.

According to analysts surveyed by FactSet, Arcus currently has an average Buy rating and a mean price target of $31.30, suggesting further upside potential for the stock.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10